COMPASS Pathways
COMPASS Pathways is a mental health company focused on developing psilocybin treatments for conditions like treatment-resistant depression, PTSD, and anorexia nervosa, with significant clinical trials underway.
Company Overview
COMPASS Pathways is dedicated to accelerating patient access to evidence-based innovation in mental health. The company is headquartered in London, UK, with additional offices in New York and San Francisco, USA. COMPASS Pathways focuses on researching and developing treatments using psilocybin for mental health conditions such as treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa.
Breakthrough Psychedelic Therapies
COMPASS Pathways is studying investigational psilocybin treatment for several mental health conditions. The company's lead product, COMP360 psilocybin, has been designated a Breakthrough Therapy by the U.S. FDA. COMPASS Pathways has also received the Innovative Licensing and Access Pathway (ILAP) designation in the UK for its treatment-resistant depression (TRD) therapy. Their ongoing research includes a phase 3 clinical program for COMP360, focusing on the largest randomized, controlled, double-blind psilocybin treatment for TRD to date.
Clinical Trials and Research
COMPASS Pathways has conducted significant clinical research, including a completed phase 2b study demonstrating that a single 25mg dose of COMP360 psilocybin with psychological support resulted in a statistically significant and clinically relevant improvement in depressive symptom severity after three weeks. The company is also conducting phase 2 clinical studies to explore the efficacy of COMP360 psilocybin for treating post-traumatic stress disorder (PTSD) and anorexia nervosa.
Key Clinical Programs
The phase 3 clinical program for COMP360 psilocybin aimed at treating treatment-resistant depression (TRD) is a noteworthy initiative by COMPASS Pathways. This program represents the largest randomized, controlled, double-blind study of psilocybin treatment ever conducted. Additionally, the company is exploring COMP360's potential in treating PTSD and anorexia nervosa through ongoing phase 2 clinical trials.